Download the ESMO 2012 Abstract Book - Oxford Journals

More documents

Recommendations

Info

Annals of Oncology are prevalent in Asian populations. However, the actual degree of understanding or perceptions of clinical trials by cancer patients in East Asian countries have seldom been studied. Methods: Between July 1st 2011 and November 30th 2011, we conducted a prospective study to survey cancer patients regarding their awareness of, and willingness to participate in, a clinical trial. The questionnaire consisted of 21 questions based on an Index of Clinical Trial Understanding. Patients with gastrointestinal/hepatobiliary cancer who visited the Hematology-Oncology outpatient clinic at Samsung Medical Center (SMC) and who signed an informed consent form were enrolled. The survey was conducted by a well-trained research nurse and the data were statistically analyzed at the biostatistics core at SMC. Results: In this survey study, 1,000 patients were asked to participate and 675 patients consented to participate (67.5%). The awareness of clinical trials was substantially higher in patients who had a higher level of education (p < 0.001), were married (p = 0.004), and had a higher economic status (p = 0.001). Willingness to participate in a clinical trial was not significantly increased by higher level of education (p = 0.286), marital status (p = 0.685), or economic status (p = 0.310). The most common source for acquisition of clinical trial knowledge was attending physicians (52.0%) followed by mass media (36.6%), other patients (6.39%), the internet (3.3%), and other sources (1.5%). The most influential factors for patient’s willingness to participate were physician’s opinion (N = 181, 26.8%), limited treatment options (N = 178, 26.4%), and expectations of effectiveness of new anti-cancer drugs (N = 142, 21.0%). Patients were likely to refuse to participate in a clinical trial due to unverified treatment modality (N = 320, 47.4%) and negativity toward clinical trials (N = 193, 28.6%). Conclusions: We surveyed a large patient cohort to specifically inquire about willingness to participate in, and awareness of, clinical trials in patients with Asian-prevalent cancer types. Further correlative analyses with diverse variables will be presented at the meeting. Disclosure: All authors have declared no conflicts of interest. 1382P AWARENESS AND UNDERSTANDING OF STRATIFIED/ PERSONALIZED MEDICINE IN PATIENTS TREATED FOR CANCER: A MULTINATIONAL SURVEY S. Tejpar 1 , T. Teague 2 , J. Lake 3 , J. Tabernero 4 , J.F. Vansteenkiste 5 , S. Vlassak 6 , F. Ciardiello 7 1 Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, BELGIUM, 2 Global Business Intelligence, Oncology, Merck KGaA, Darmstadt, GERMANY, 3 Vivian Road, Mile End, London, UNITED KINGDOM, 4 Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, SPAIN, 5 Respiratory Oncology Unit (Pulmonology), University Hospital Gasthuisberg, Leuven, BELGIUM, 6 Global Clinical Development Unit-oncology, Merck KGaA, Darmstadt, GERMANY, 7 Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery "F. Magrassi and A. Lanzara", Second University of Naples, Naples, ITALY Background: The identification of biomarkers predictive for the efficacy of targeted anticancer agents allows for the tailoring of treatment to maximize patient (pt) benefit and outcomes. It is important that information about the potential for the personalization of anticancer therapy is available to pts so that they are fully informed about treatment and biomarker screening options. The current survey assessed pt awareness and understanding of these issues. Methods: Pts with a diagnosis of late-stage breast cancer (BC), stage III/IV non-small cell lung cancer (NSCLC) or metastatic colorectal cancer (mCRC) within the previous 5 years were eligible. Participating physicians or pt organizations in seven countries (Argentina, China, France, Germany, Italy, Spain and the UK) identified potentially suitable pts and invited them to take part. Written informed consent was obtained from all pts, with those confirmed as eligible then completing a telephone-based questionnaire. Results: Questionnaires were completed by 811 pts: 164 previously diagnosed with BC; 157 with NSCLC and 490 with mCRC. Of those interviewed: 260/811 pts (32%) thought that there was no method of testing to determine which cancer treatments might work (or work better) in certain people, while 430/811 pts (53%) thought that such testing might be possible (62% of pts with BC, 48% with NSCLC and 52% with mCRC). Most pts (532/811, 66%) were willing to delay treatment if that helped select the most effective drug, 286/532 (54%) of those, by more than two weeks, and most (557/811, 69%) were willing to undergo a tumor re-biopsy as part of any such treatment selection process. Almost all pts (737/811, 91%) would allow a hospital to retain a tumor sample for future research. The internet was cited as a useful source of information regarding disease and treatment options by 192/811 pts (24%). Conclusions: Pts are generally willing to participate in biomarker test procedures to facilitate the personalization of their treatment. There is considerable scope for physicians and support groups to better inform pts that not all cancers are the same and that new tests may be able to identify which treatments will work most effectively for them. Disclosure: S. Tejpar: The author declares research and speakers’ bureau funding from Merck Serono. T. Teague: The author is an employee of Merck KGaA. J. Tabernero: The author declares: Consultant or Advisory Role (compensated) : Amgen, Bristol-Myers Squibb, Genentech, Merck KGaA, Millennium, Novartis, Onyx, Pfizer, Roche and Sanofi Honoraria: Amgen, Merck KGaA, Novartis, Roche and Sanofi. S. Vlassak: I am an employee for Merck Serono in the medical department. All other authors have declared no conflicts of interest. 1383P WHEN DOES PERSONALIZED CANCER THERAPY RESEARCH PROVIDE POSITIVE RETURN ON INVESTMENT IN EUROPE? H.J. Conter 1 , D. Conter 2 , R.A. Wolff 3 1 Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA, 2 Philisophy, Huron College, London, ON, CANADA, 3 Gastrointestinal Medical Oncology, UT M.D. Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA Background: Personalized cancer therapies targeting pre-specified genetic mutations currently benefits only subsets of patients. Developing the technologies and supporting the research to identify new targets and treatments requires a significant monetary outlay. How much money should the European public invest in such research? Methods: Since current investment should be less than or equal to the net-present-value (NPV) of the future health gains achieved, the marginal benefit gained from a new drug can be estimated by calculating the difference between the incremental cost-effectiveness ratio (ICER) and the willingness-to-pay (WTP) for the increase in health by society. We calculated the NPV of the future development for new drugs with similar characteristics to crizotinib, a prototypic personalized cancer therapy. Sensitivity analyses were performed to assess the influence of WTP thresholds, time horizon of return, and size of treatable population. Systematic reviews of PubMed and EMBASE were employed to determine the current range of ICERs for approved small-molecule inhibitors and monoclonal antibodies, and WTP thresholds. European cancer statistics were used to estimate the size of population who may benefit. Results: Of 1576 titles, 104 abstracts and manuscripts were included in the final analysis. The median ICER for targeted therapies was €45,000 (range, €10,000-€163,000), and median WTP was €50,000 (range, €12,000-€152,000). With a development time horizon of 8 years, €840 million in research funding provides positive societal returns for new pharmaceuticals bought at a marginal value of greater than €5,000. Doubling the time horizon reduces the NPV of current research by €230 million. If current-generation personalized therapies are dominated by newer technologies earlier than predicted, halving their market-life as an example, only €500 million in public investment would be worthwhile. The NPV of research was highly sensitive to changes in the estimated size of the treatable population. Focusing on drug development for breast, lung, and colon cancer only, may yield a NPV for research of €1.34 billion. Conclusion: Regional differences in cancer incidence and WTP for new therapeutics should be formally incorporated into research funding decisions to ensure optimal resource allocation. Disclosure: All authors have declared no conflicts of interest. 1384P ARE THERE DIFFERENCES IN PATIENT CHARACTERISTICS AND TREATMENT PATTERNS BY TREATMENT SETTING? C. Reyes 1 , S. Dacosta Byfield 2 , A. Small 3 1 Health Outcomes & Payer Support US Medical Affairs, Genentech, San Francisco, CA, UNITED STATES OF AMERICA, 2 HEOR - Observational Reserach, OptumInsight, Eden Prairie, MN, UNITED STATES OF AMERICA, 3 Oncology, Outcomes Research, Us Meidcal Affairs, Genentech, San Francisco, CA, UNITED STATES OF AMERICA Background: Few studies have examined whether differences in treatment and outcomes exist among cancer patients by the setting where care is delivered. This study investigates differences in demographics, treatment patterns and health care resource use among non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) patients receiving rituximab (R) or R+ chemotherapy based on site of care: office/clinic (OC) vs. hospital outpatient (HO). Methods: Patients ≥18 years with evidence of NHL or CLL diagnoses codes at least 30 days apart and received ≥2 R claims from Jan 2007 to Mar 2011 were identified from a large US commercial insurance claims database. Patients were required to be enrolled in the health plan for at least 6 months before and after the index date (date of first R claim). The follow-up period was the date of the first infusion to 30 days after the last infusion prior to a gap of ≥7 months. Patients with evidence of multiple cancers or receipt of R at both sites of care were excluded. Cohorts were created based on site of care where R was administered. Multivariate analyses examined differences in number of infusions, ER visits and inpatient stays by cohort. Results: There were 2,594 OC and 286 HO patients with a mean follow-up of 242 days and 209 days, respectively. Compared to the HO cohort, the OC patients were significantly younger (71yrs vs. 63 yrs), had a lower mean baseline Charlson comorbidity index (3.88 vs. 3.40) and a lower percentage were Medicare Volume 23 | Supplement 9 | September 2012 doi:10.1093/annonc/mds410 | ix451
Advantage enrollees (83% vs. 25%) [each p < 0.01]. The mean R infusion count was 7.4 (OC) vs. 5.4 (HO) with a monthly mean of 1.19 (OC) vs. 1.00 (HO) [each p < 0.01]. In adjusted analyses, R infusion counts were also lower for HO compared to the OC cohort (IRR 0.80, CI 0.75-0.86) and HO patients had higher number of inpatient stays (IRR 1.40, CI 1.07-1.84) though ER visits were not different between cohorts. Conclusions: Patients treated in the OC setting compared to the HO setting had different treatment patterns and fewer inpatient stays. These results warrant further investigation to assess whether clinical outcomes differ by site of care. Disclosure: C. Reyes: Has Roche stock and employment at Genentech/Roche. S. Dacosta Byfield: Employed at OptumInsight, the entity that was paid by Genentech to conduct the study. A. Small: Has Roche stock and employment at Genentech/Roche. 1385P ABBREVIATED COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) IN ELDERLY CANCER PATIENTS: PRELIMINARY RESULTS OF AN OBSERVATIONAL PILOT STUDY O. Mora 1 , L. Marelli 2 , P. Quadri 3 , M. Tettamanti 4 , C. Pedrazzani 2 , M. Ghielmini 5 1 Oncology, IOSI Istituto Oncologico Svizzera Italiana, Bellinzona, SWITZERLAND, 2 Medical Oncology, IOSI Istituto Oncologico Svizzera ItalianaOspedale Regionale Bellinzona e Valli, Bellinzona, SWITZERLAND, 3 Internal Medicine, Geriatric Department, Ospedale Beata Vergine, Mendrisio, SWITZERLAND, 4 Neuroscience, Istituto Mario Negri, Milano, ITALY, 5 Medical Oncology, IOSI Ospedale San Giovanni, Bellinzona, SWITZERLAND Background: In Western countries elderly people constitute the fastest growing segment of the population and currently in our Institute patients aged ≥70 are about 45% of all cancer patients. CGA is a key component of the treatment approach for this population, but it is time-consuming. Methods: This is an observational pilot study on consecutive therapy-naive elderly cancer patients (aged ≥ 70 years). The main aims were to verify the feasibility of an abbreviated CGA (aCGA) in an outpatient setting, the acceptability by patients, physicians, and nurses as well as the ability of this tool to discriminate the three prognostic classes of older cancer patients: fit, vulnerable, frail. Patients underwent aCGA (which consisted in filling in some short questionnaires, instead of the standard ones) with a medical oncologist (medical history, clinical examination, ECOG-performance status, Cumulative Illnesses Rating Scale-CIRS) and with a nurse (Activities Daily Living-ADL, Instrumental ADL, Mini Nutritional Assessment-MNA, cognitive Short Blessed Test, Geriatric Depression Scale-GDS, Quality of Life Health Survey-SF-12, motor status). Results: From January 2010 to November 2011, 151 patients were enrolled. Median age was 77 (70-91) years, and 47% were males. Patients, doctors and nurses evaluated the information obtained by aCGA as, respectively: very useful in 47, 66, 42% and quite useful in 47, 28, 52%. The time required for the compilation of the questionnaires with nurses was 60 min in 17%. Physicians considered to have had no difficulty (83%) or little difficulty (10%) in compiling the form,. For nurses these figures were 40% and 43%. aCGA allowed to differentiate patients into three prognostic classes: fit 34%, vulnerable 36%, and frail 30%. Each of these classes was proposed for treatment which was curative in 76, 55, 35% of cases, palliative in 20, 35, 27% and supportive in 4, 10, 38% of cases, respectively. Conclusions: aCGA is feasible in the outpatient setting. It is usually well accepted by patients, medical staff and nurses. It allows a distinction of prognosis of elderly cancer patients favouring an appropriate therapeutic choice. Disclosure: All authors have declared no conflicts of interest. 1386P WILL ‘FIT’ OLDER CANCER PATIENTS AS ASSESSED BY FRAILTY SCREENING TOOLS TOLERATE THE FIRST CYCLE OF (RADIO) CHEMOTHERAPY WITHOUT SERIOUS ADVERSE EVENTS? A. Baitar 1 , F. van Fraeyenhove 1 , A. Vandebroek 1 , E. De Droogh 2 , D. Galdermans 2 , J. Mebis 3 , D. Schrijvers 1 1 Medical Oncology, ZNA Middelheim, Antwerp, BELGIUM, 2 Pulmonology, ZNA Middelheim, Antwerp, BELGIUM, 3 Medical Oncology, Virga Jessa Hospital, Hasselt, BELGIUM Background: There is a need for tools to effectively select elderly cancer patients for therapies with significant potential toxicity such as chemotherapy. The Comprehensive Geriatric Assessment (CGA) is recommended by several guidelines to guide the oncologist in treatment decision making. However, because CGA is time and man-power consuming a two-step approach with screening has been recommended. This pilot study was undertaken to evaluate the predictive value of 2 frailty screening tools in relation to the tolerability of chemotherapy in ‘fit’ older cancer patients. Methods: Patients over 65 years with various types and stages of cancer were screened for CGA before start of treatment with the Groningen Frailty Indicator (GFI) and the G8 screening tool. ‘Fit’ patients were defined as having a normal Annals of Oncology screening test. A G8 score of ≤14 corresponds with an abnormal screening test. For the GFI we evaluated 2 cut-off values. Serious adverse events (SAE) were recorded during the first cycle of treatment. Results: From October 2009 to December 2011, 85 patients (44 women) were included in the study. The median age was 76 years old (range: 66-88 years). The treatment intent was curative in 39 patients (46%) and palliative in 46 patients (54%). In total, 15 patients (18%) had a SAE of which 3 resulted in death. According to the GFI, 60% were ‘fit’ while the G8 identified 30% as ‘fit’ prior to treatment. The probability to complete the 1e cycle of chemotherapy without a SAE for ‘fit’ patients was according to the G8 and the GFI (cut-off ≥4) respectively 77% (95%CI: 63-89%) and 78% (95%CI: 73-86%). The alternative cut-off ≥3 for the GFI resulted in probability of 85% (95%CI: 73-94%) to tolerate treatment. Conclusion: Patients with a normal screening test for CGA are considered to be able to tolerate proposed treatments comparable to younger patients. However, no data exist concerning this assumption. In this study, we attempted to address this in a heterogenic sample of older cancer patients for 2 screening tools. Further research is needed to compare standard of care with this CGA-based approach with screening. Disclosure: All authors have declared no conflicts of interest. 1387P PREDICTORS OF NONCOMPLETION OF CANCER TREATMENTS IN ELDERLY PATIENTS: THE ELDERLY CANCER PATIENTS (ELCAPA) COHORT STUDY M. Laurent 1 , E. Paillaud 1 , M. Carvalho-Verlinde 2 , P. Caillet 1 , A. Le Thuaut 3 , E. Liuu 1 , S. Bastuji-Garin 3 , S. Culine 4 , F. Canouï-Poitrine 3 1 Consultation d’Onco-Gériatrie (UCOG Créteil), AP-HP, Hôpital Henri-Mondor, Département de Médecine Interne et Gériatrie, Créteil, FRANCE, 2 Service de Pharmacie, AP-HP, Hôpital Henri-Mondor, Créteil, FRANCE, 3 Pôle Recherche Clinique et Santé Publique, AP-HP, Hôpital Henri-Mondor, Créteil, FRANCE, 4 Oncology, Hôpital Saint-Louis, Paris, FRANCE Background: The objective was to assess 1) prevalence and the predictors of non-completion of cancer treatments in elderly and 2) prognosis value of noncompletion of cancer treatments. Methods: Between 2007-2010, 421 consecutive patients aged 70 years and older with solid tumors and indication of surgery, chemotherapy (CT), hormonal therapy (HT) or radiotherapy (RT) were included. Comprehensive Geriatric Assessment was performed at baseline. Patients were followed up for completion of surgery, first line CT (observed/expected number of cycles < 1), RT and HT (observed/expected dose < 1) and one year overall survival. Multivariate logistic regression and Cox -Proportional Hazard Model were used to estimate predictors of noncompletion treatments and survival. Results: Mean age was 79.2 years (±5.4) years and 224 patients (53.2%) were women.190 (45. 1%) had gastro-intestinal, 109 (25.9%) gynaecologic and 97 (23%) genitor-urinary primary tumors.192 (45.6%) had metastatic disease. 76 (33.8%) received platinum-based therapy. • Rate of noncompletion was 39.1 % for CT versus 6.5 %, 3.5 % and 2.4 % for HT, surgery and RT respectively. In multivariate analysis, predictors of noncompletion of CT were: poor performance status (PS ≥ 2) : OR = 2.1, 95 %CI, [1.06-4.17], p = 0.03, (or Activity of Daily Living (ADL): OR 1 point decrease= 1.5, [1.1-2.0], p= 0.024), decreased renal function: OR 1 ml/min decrease Cockcroft clearance = 1.02, [1-1.03],p= 0.009 and living alone :OR = 1.9, [1-3.6], p = 0.05. One year rate of mortality was 26.2 %. Independant prognostic factors for survival were noncompletion of CT: HR = 3.6, [2.2-6], p < 0.0001, a poor functional status (ADL HR 1 point decrease =1.5, [1.3-1.9], p < 0.0001, metastatic disease:.HR = 3.3, [1.7-6.3], p < 0.0001 and malnutrition: HR = 2.6, [1.6-4.4], p < 0.0001. Conclusion: In the elderly with solid tumors, noncompletion of CT was common whereas HT, RT and surgery were not. Predictors of noncompletion of CT are poor functional status, decreased renal function and living alone. Noncompletion of CT is an independent prognostic factor for survival. Disclosure: All authors have declared no conflicts of interest. 1388P COMPLEMENTARY AND ALTERNATIVE MEDICINES (CAM) – A CURSE TO BREAST CANCERS OF THE INDIAN SUBCONTINENT K. Chatterjee1 , S.K. Sarkar2 , S.K. Mondal3 , J. Goswami4 , B. Chatterjee5 1 Oncology, Institute of Post Graduate Medical Education and Research (IPGMER&SSKM Hospital) Kolkata, Kolkata, INDIA, 2 Oncology, Medical College Kolkata, Kolkata, INDIA, 3 Oncology, R.G Kar Medical College and Hospital, Kolkata, INDIA, 4 Radiation Oncology, West Bank Hospital, Howrah, INDIA, 5 Medicine, Mahesh Bhattacharyya Homeopathic P.G Medical College and Hospital, Howrah, INDIA Purpose: In India, CAM practitioners get a major share of the first visits by patients with breast lumps, leading to inadvertent delays in their management. This multi-institutional prospective study conducted in IPGMER, M.C.H & R.G Kar, Kolkata, aims to quantify the exact percentage prevalence of CAM usage, ix452 | Abstracts Volume 23 | Supplement 9 | September 2012
Page 1 and 2:
Annals of Oncology www.annonc.oxfor
Page 3 and 4:
subscriptions A subscription to Ann
Page 6 and 7:
Annals of Oncology Official Journal
Page 8 and 9:
The European Society for Medical On
Page 10 and 11:
Audit Committee Chair: Fortunato Ci
Page 12 and 13:
Familial cancer Judith Balmaña, Ba
Page 14 and 15:
ESMO 2012 Congress Travel Grants 47
Page 16 and 17:
Exhibitors The following companies
Page 18 and 19:
ESMO Fellowships, 1989-2011 The Eur
Page 20:
Ondrej Gojis, Czech Republic 2008-2
Page 23 and 24:
abstracts hpv biology and implicati
Page 25 and 26:
abstracts the characterization of l
Page 27 and 28:
abstracts description of intra-tumo
Page 29 and 30:
prevent cell death. It is anticipat
Page 31 and 32:
22IN TARGETING THE HOST IN TNBC G.
Page 33 and 34:
abstracts a paradigm shift in early
Page 35 and 36:
abstracts how can medical oncologis
Page 37 and 38:
feasibility), but by how high the c
Page 39 and 40:
abstracts re-inventing the medical
Page 41 and 42:
abstracts emerging diagnostic and t
Page 43 and 44:
abstracts biologically based treatm
Page 45 and 46:
abstracts molecular targets in mali
Page 47 and 48:
abstracts melanoma therapy: from fr
Page 49 and 50:
diagnosis and can also be used for
Page 51 and 52:
analysis at 11 months median follow
Page 53 and 54:
mouse model of Kras mutant NSCLC. I
Page 55 and 56:
abstracts subtyping soft tissue sar
Page 57 and 58:
abstracts key topics in supportive
Page 59 and 60:
ESMO-CSCO Joint Symposium: Building
Page 61 and 62:
ESMO-EANM-ESR Joint Symposium: Imag
Page 63 and 64:
ESMO-ESTRO Joint Symposium: Innovat
Page 65 and 66:
ESMO-MASCC Joint Symposium: Integra
Page 67 and 68:
ESO Society Symposium: Celebrating
Page 69 and 70:
Results: TIMP-1 expression was incr
Page 71 and 72:
will benefit from this targeted the
Page 73 and 74:
cytomegalovirus (CMV). Analysis of
Page 75 and 76:
functional consequences of Endoglin
Page 77 and 78:
elationship between the ROR score,
Page 79 and 80:
183P EPIDERMAL GROWTH FACTOR RECEPT
Page 81 and 82:
Plasma adiponectin level on the pre
Page 83 and 84:
Table: 198P PFS OS Median, mo HR Me
Page 85 and 86:
204P EVALUATION OF PTEN AND PIK3CA
Page 87 and 88:
Material and methods: We searched P
Page 89 and 90:
Results: The median concentration o
Page 91 and 92:
Table: 226P Methods: Pts were rando
Page 93 and 94:
However, additional analysis sugges
Page 95 and 96:
number of biomarkers have been trie
Page 97 and 98:
Table: 248O 249PD PROTEOMIC PREDICT
Page 99 and 100:
Conclusions: BW and serum Ctrough o
Page 101 and 102:
261P BREAST CANCER SUBTYPES AND OUT
Page 103 and 104:
90 mg/m2-cyclophophamide 600 mg/m2
Page 105 and 106:
to 9 weeks after dosing. Trastuzuma
Page 107 and 108:
Patients and methods: We reviewed d
Page 109 and 110:
sector patients. The aim of this st
Page 111 and 112:
Linear Logistic Model with Relaxed
Page 113 and 114:
Results: The median CTC fold change
Page 115 and 116:
312: Table: Chemotherapy uptake wit
Page 117 and 118:
abstracts breast cancer, locally ad
Page 119 and 120:
Results: 8 trials (2092 pts) with 1
Page 121 and 122:
absolute difference of median value
Page 123 and 124:
Novartis, Genentech, and sanofi-ave
Page 125 and 126:
Results: Three RCTs with 1023 patie
Page 127 and 128:
collected from all patients for det
Page 129 and 130:
355P FIRST REPORT OF LONG-TERM RESP
Page 131 and 132:
361P A RETROSPECTIVE ANALYSIS OF PL
Page 133 and 134:
publications and aggregated in a me
Page 135 and 136:
Thus the primary aim to target BCSC
Page 137 and 138:
383 WHY DO WOMEN WITH BREAST CANCER
Page 139 and 140:
Results: We evaluated 76 pts with M
Page 141 and 142:
more than 6 cycles of capecitabine.
Page 143 and 144:
406TiP PHASE II TRIAL OF PRIMARY SY
Page 145 and 146:
abstracts CNS tumors 410O CONDITION
Page 147 and 148:
Conclusions: Our data suggested tha
Page 149 and 150:
Conclusions: As in other cancer typ
Page 151 and 152:
432 GAMMA KNIFE RADIOSURGERY AS A M
Page 153 and 154:
abstracts developmental therapeutic
Page 155 and 156:
1PR), but no responses were seen in
Page 157 and 158:
RO and Cd, as well as PD data for c
Page 159 and 160:
and vulvar Ca), and 11 SDs were obs
Page 161 and 162:
knowing HLA-A status double-blindly
Page 163 and 164:
Acquired-resistance to EGFR inhibit
Page 165 and 166:
474P PHASE 1 STUDY OF THE SELECTIVE
Page 167 and 168:
TST is active in breast and gastric
Page 169 and 170:
Treatment-induced shedding of circu
Page 171 and 172:
Methods: Either co-cultures of peri
Page 173 and 174:
501 PRECLINICAL DATA INVESTIGATING
Page 175 and 176:
509TiP LUX-LUNG 8: A RANDOMIZED, OP
Page 177 and 178:
(P = 0.64). Synchronous BBC was sig
Page 179 and 180:
abstracts gastrointestinal tumors,
Page 181 and 182:
Disclosure: M. Lee: I am an employe
Page 183 and 184:
plus intravenous Bev(7.5mg/kg q 21d
Page 185 and 186:
anti-EGFR treatment. The present st
Page 187 and 188:
patients harboring a T/T genotype t
Page 189 and 190:
551P ADJUVANT CHEMOTHERAPY (AC) USE
Page 191 and 192:
experienced significantly more ≥
Page 193 and 194:
functioning scales. Exploratory ana
Page 195 and 196:
oxaliplatin (100 mg/m 2 )/raltitrex
Page 197 and 198:
572P PANERB STUDY: WHICH CATEGORY O
Page 199 and 200:
Results: 92/114 patients were preop
Page 201 and 202:
585P CHANGES IN THE INTESTINAL ENVI
Page 203 and 204:
592P PHASE II TRIAL OF COMBINED CHE
Page 205 and 206:
minutes. In a previous study, 30-mi
Page 207 and 208:
Patients and methods: Chemotherapy-
Page 209 and 210:
612P ARE PATIENTS WITH RESECTABLE R
Page 211 and 212:
Conclusions: AMPK and ACC activatio
Page 213 and 214:
of surgical monotherapy in patients
Page 215 and 216:
Table: 632 633 AFLIBERCEPT/FOLFIRI
Page 217 and 218:
factors play the determining role i
Page 219 and 220:
Abstract withdrawn in exceptional c
Page 221 and 222:
were respectively 10.6 vs 8.5 vs 3.
Page 223 and 224:
Results: 20 gastrointestinal cancer
Page 225 and 226:
abstracts gastrointestinal tumors,
Page 227 and 228:
Day 8. A second identical course wa
Page 229 and 230:
proven in stage I GC. The aim of th
Page 231 and 232:
Conclusions: Longer OS to FOLFOX wa
Page 233 and 234:
692P PRELIMINARY SAFETY DATA FROM A
Page 235 and 236:
subgroup. Taking into consideration
Page 237 and 238:
Results: Three years of adjuvant im
Page 239 and 240:
considered sufficient to give an 80
Page 241 and 242:
721P FIRST-LINE TREATMENT WITH FOLF
Page 243 and 244:
after Gem-based therapy. The additi
Page 245 and 246:
735P RADIOGRAPHIC PARAMETERS IN PRE
Page 247 and 248:
validate the revised AJCC 7th stagi
Page 249 and 250:
Results: Among 862 MM we identified
Page 251 and 252:
Results: Frequently reported advers
Page 253 and 254:
gastric cancer patients with CNS me
Page 255 and 256:
discriminate the prognosis of HCC p
Page 257 and 258:
prospective, non-interventional stu
Page 259 and 260:
abstracts genitourinary tumors, non
Page 261 and 262:
787O EXTERNAL VALIDATION OF THE ASS
Page 263 and 264:
patient preference for P over S, an
Page 265 and 266:
798PD OPEN-LABEL PHASE II TRIAL OF
Page 267 and 268:
Hb, PS and LM. Median PFS for patie
Page 269 and 270:
may have led to reduced dose and sh
Page 271 and 272:
Results: 1,622 patients were identi
Page 273 and 274:
RCC) was designed to address an unm
Page 275 and 276:
Patients and methods: This is a sin
Page 277 and 278:
treatment at week 4, and week 12 by
Page 279 and 280:
effective in second or further line
Page 281 and 282:
Conclusions: In pts with RCC treate
Page 283 and 284:
using Drug inCode ® pharmacogeneti
Page 285 and 286:
Table: 857P standard, but is not av
Page 287 and 288:
efused HDCT. Of 23 patients, 20 com
Page 289 and 290:
we identified 49 and 220 patients w
Page 291 and 292:
879 TREATMENT OF PATIENTS WITH META
Page 293 and 294:
Median overall survival (OS) was 26
Page 295 and 296:
abstracts Genitourinary tumors, pro
Page 297 and 298:
and week 13 BPI-SF Q3 scores), 28%
Page 299 and 300:
Working Group (PCWG)-2 guidelines r
Page 301 and 302:
atio HR 0.39; CI 0.18, 0.83, p = 0.
Page 303 and 304:
We observed tumor responses and pro
Page 305 and 306:
Here we report emerging data from t
Page 307 and 308:
928P LHRH AGONIST-INDUCED SUPPRESSI
Page 309 and 310:
Disclosure: S. Oudard: Has acted as
Page 311 and 312:
939P NEOADJUVANT SIPULEUCEL-T IN LO
Page 313 and 314:
945 BONE TURNOVER MARKERS AND POTEN
Page 315 and 316:
952 SEQUENTIAL ANDROGEN DEPRIVATION
Page 317 and 318:
managed in a multidisciplinary (MD)
Page 319 and 320:
or hypercalcemia at screening; prio
Page 321 and 322:
meeting. The prevalence of LGSC is
Page 323 and 324:
Table: 975PD Continued AMG 386 + pa
Page 325 and 326:
physicians in the U.S. and Europe.
Page 327 and 328:
989P PHASE II STUDY OF COMBINATION
Page 329 and 330:
elated with stage, nodal involvemen
Page 331 and 332:
1004P CASE CONTROL STUDY ON TWO DIF
Page 333 and 334:
eight patients who had infertility
Page 335 and 336:
abstracts head and neck cancer 1016
Page 337 and 338:
same CT/RT; Arm B2: 3 cycles of ind
Page 339 and 340:
induction chemotherapy in the treat
Page 341 and 342:
patients. We have developed a rando
Page 343 and 344:
evaluated by the screening instrume
Page 345 and 346:
morbidities that radiation would le
Page 347 and 348:
Conclusions: Through adequate selec
Page 349 and 350:
abstracts hematological malignancie
Page 351 and 352:
anthracyclines in vitro. A favorabl
Page 353 and 354:
1076P RITUXIMAB PLUS SUBCUTANEOUS C
Page 355 and 356:
than the standard target of ≥2.5
Page 357 and 358:
Patients: From November 2002 to May
Page 359 and 360:
lymphadenopathy and multiple cutane
Page 361 and 362:
prospective non-interventional stud
Page 363 and 364:
Funding: GSK Biologicals Disclosure
Page 365 and 366:
survival rates of 13-25% (Prieto et
Page 367 and 368:
high response rates and prolonged p
Page 369 and 370:
GlaxoSmithKline, Merck Sharp & Dohm
Page 371 and 372:
advisor for Merck Sharp & Dohme, an
Page 373 and 374:
or cutaneous melanoma. A survival u
Page 375 and 376:
systemic therapy or were intolerant
Page 377 and 378:
abstracts neuroendocrine tumors and
Page 379 and 380:
morbidity, with G3 tumors behaving
Page 381 and 382:
pts. Poorly differentiated endocrin
Page 383 and 384:
Adenocarcinoma was present in 25 pa
Page 385 and 386:
Method: Endobronchial ultrasound gu
Page 387 and 388:
widely used by single agent or plat
Page 389 and 390:
disease after surgery were treated
Page 391 and 392:
stage IIIA NSCLC, EML4-ALK fusion-p
Page 393 and 394:
1200P CONCOMITANT CHEMORADIATION GI
Page 395 and 396:
Patients and methods: The study was
Page 397 and 398:
months (95% CI:13-25). The PFS and
Page 399 and 400:
maintenance therapy had favourable
Page 401 and 402: abstracts non-small cell lung cance
Page 403 and 404: Ingelheim, GSK Biologicals (compens
Page 405 and 406: 1234PD RANDOMIZED PHASE III TRIAL O
Page 407 and 408: GlaxoSmithKline (myself, compensate
Page 409 and 410: 1243P IDENTIFICATION OF MICRORNA (M
Page 411 and 412: N-arm n=34 P-arm n=32 All n=66 Male
Page 413 and 414: 1255P POPULATION BASED EVALUATION O
Page 415 and 416: 1262P DISTINCT SPREAD OF EGFR MUTAT
Page 417 and 418: 1268P VISUAL DISTURBANCES IN PATIEN
Page 419 and 420: MERCK SERONO: Advisor, speaker in s
Page 421 and 422: Conclusions: These data from SAiL a
Page 423 and 424: NSCLC diagnosis and time of BM diag
Page 425 and 426: 1291P PHASE I/II DOSE-FINDING STUDY
Page 427 and 428: Network utilization of WBCGF in the
Page 429 and 430: 1303P COST EFFECTIVENESS OF PEMETRE
Page 431 and 432: Results: The patients’ characteri
Page 433 and 434: EGFR mut at exons 18, 19, 21, and K
Page 435 and 436: Methods: EML4-ALK fusion was screen
Page 437 and 438: Results: The median survival time (
Page 439 and 440: enefit from sustained EGFR blockade
Page 441 and 442: epresented by 19 pts (32%) female,
Page 443 and 444: and at least one prior course of ch
Page 445 and 446: Methods: NSCLC patients with radiog
Page 447 and 448: 1367TiP LONG-TERM ERLOTINIB THERAPY
Page 449 and 450: Austria, Czech Republic, Finland, G
Page 451: were every 6 weeks (wk) (S1), every
Page 455 and 456: Results: Based on 10,000 simulation
Page 457 and 458: cancer tumors 12%, Germ cell tumor
Page 459 and 460: Material and methods: 50 lung cance
Page 461 and 462: 1414TiP IMPLEMENTATION OF CANCER RE
Page 463 and 464: abstracts palliative care 1422O EFF
Page 465 and 466: Method and results: A total of 317
Page 467 and 468: 1436P SURVEY ON MODELS OF INTEGRATI
Page 469 and 470: care unit (PCU) at the National Can
Page 471 and 472: Characteristic No. % Total 63 1 st
Page 473 and 474: hysterectomised-9.10% and cervix ca
Page 475 and 476: abstracts psycho-oncology 1462PD IN
Page 477 and 478: events, tumour response, and surviv
Page 479 and 480: abstracts sarcoma 1477O ADHESION TO
Page 481 and 482: 1481PD A PHASE II STUDY OF DOVITINI
Page 483 and 484: 1488P ORGANISATION OF SARCOMA PATIE
Page 485 and 486: Patients and methods: From August 2
Page 487 and 488: chemotherapy respectively. At a med
Page 489 and 490: of this group Those with relapsed d
Page 491 and 492: 1515 PREDICTORS OF SURVIVAL IN ADOL
Page 493 and 494: abstracts small cell lung cancer an
Page 495 and 496: emaining receiving either CAV or to
Page 497 and 498: 1533P EXPRESSION OF WILM⍰TUMOUR G
Page 499 and 500: more than 3 months after first line
Page 501 and 502: lower recurrence rate of NE. Pegfil
Page 503 and 504:
egimens (HR = 2.5, p < 0.001). Phys
Page 505 and 506:
1561P PREDICTIVE DIAGNOSTICS FOR RE
Page 507 and 508:
Methods: A prospective multicentre
Page 509 and 510:
Table: 1574P Pharmacokinetic parame
Page 511 and 512:
Novartis and unrestricted research
Page 513 and 514:
studies have shown that chemotherap
Page 515 and 516:
(Grade 1) and moderate to severe (G
Page 517 and 518:
declined to relatively lower level
Page 519 and 520:
1609P PHYSICAL ACTIVITY (PA) AND PH
Page 521 and 522:
patients were admitted to the oncol
Page 523 and 524:
Dicarbamin 100 mg/day on day 5 befo
Page 525 and 526:
Results: Anemia was detected in 83.
Page 527 and 528:
important to carry out randomized s
Page 529 and 530:
abstracts translational research 16
Page 531 and 532:
expression. Then, we analyzed PB sa
Page 533 and 534:
Table: 1657P TH BV + TH HR (95% CI)
Page 535 and 536:
BRAF mutations. Circulating free DN
Page 537 and 538:
1671P PHASE I CLINICAL TRIAL OF CAN
Page 539 and 540:
1678P PREDICTIVE VALUE OF TWO PHENO
Page 541 and 542:
theorized that the PI3K/AKT pathway
Page 543 and 544:
Material and methods: 101 patients
Page 545 and 546:
overexpressing and 232 had triple n
Page 547 and 548:
author index author index A Aamdal
Page 549 and 550:
author index Badran A. ix288 (874)
Page 551 and 552:
author index Bösmüller H. ix209 (
Page 553 and 554:
author index Chen A. ix319 (966O) C
Page 555 and 556:
author index De Droogh E. ix452 (13
Page 557 and 558:
author index Esposito G. ix209 (618
Page 559 and 560:
author index Geiges G. ix306 (930P)
Page 561 and 562:
author index Hartono S. ix70 (155P)
Page 563 and 564:
author index Iwasaki H. ix542 (1694
Page 565 and 566:
author index Kodaira M. ix90 (228P)
Page 567 and 568:
author index Lichtensztejn D. ix350
Page 569 and 570:
author index Martinez A. ix496 (153
Page 571 and 572:
author index Morishita N. ix432 (13
Page 573 and 574:
author index Okamoto N. ix432 (1320
Page 575 and 576:
author index Piau S. ix456 (1401P)
Page 577 and 578:
author index Rodríguez Rodríguez
Page 579 and 580:
author index Scoggins C.R. ix371 (1
Page 581 and 582:
author index Stern L. ix272 (823P)
Page 583 and 584:
author index Trypaki M. ix429 (1308
Page 585 and 586:
author index Whitmore J.B. ix310 (9
Page 587 and 588:
subject index subject index A AAV-H
Page 589 and 590:
subject index ix115 (316TiP), ix116
Page 591 and 592:
subject index diffuse large B-cell
Page 593 and 594:
subject index (1033P), ix340 (1036P
Page 595 and 596:
subject index medical information,
Page 597 and 598:
subject index (612P), ix214 (633),
Page 599 and 600:
subject index RCC, ix274 (830P) re-
Page 601 and 602:
subject index TR-FRET, ix84 (206P)
Page 603 and 604:
drug index drug index 1248P, 1250P,
Page 605 and 606:
translational research index transl
Page 607 and 608:
Page 609:
show all

Download the ESMO 2012 Abstract Book - Oxford Journals

Create successful ePaper yourself

Delete template?

Save as template?